Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Attack II - A Complete Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Paul Shread who wrote (21165)	10/9/2001 10:30:23 AM
From: Frederick Langford	Respond to of 52237

-------------------------------------------------------------------------------- Myriad Genetics Says It Finds Cancer Drug Target October 09, 2001 08:50:12 (ET) SALT LAKE CITY, Oct 9 (Reuters) - Myriad Genetics Inc. (MYGN,Trade) said on Tuesday it has discovered a novel drug target for the treatment of a broad range of cancers and has initiated tests with a series of compounds that selectively kill cancer cells. Its stock was up sharply in pre-opening trade, indicated with a bid of $42.30 and an asking price of $35.36. The stock closed at $34.78 on Monday. The anti-cancer target was discovered using Myriad's ProNet proteomics technology to investigate the process leading to normal programmed cell death, Myriad said. Pre-clinical studies have demonstrated strong anti-cancer activity in compounds without harming normal human cell survival, the company said. Myriad said its researchers found that MPI-176716 induces apoptosis, or cell death, in several cancers, including prostate cancer cells and T cell lymphomas. "The compounds we are developing against this target show broad anti-cancer activity," Myriad President Dr. Adrian Hobden said in a statement. Fred